Gardasil dose reduction could boost EU sales for Merck-Sanofi joint venture

Now that the European Commission has officially approved a two-dose Gardasil regimen for early teens, Merck and Sanofi–who market the HPV vaccine in Europe through joint venture Sanofi Pasteur MSD–will see the number of shots per patient fall.

GlaxoSmithKline steps up bribery probes, eyeing potential violations in 9 Middle Eastern countries

GlaxoSmithKline has added two more countries to its bribery-investigation list. The U.K.-based drugmaker now says it faces probes in Jordan and Lebanon, in addition to recently announced investigations in Iraq and Poland.

Under fire from local pharmas, China backs off price caps

On Tuesday, the Chinese government quietly announced that it is easing up on its policy of restricting drug prices and will allow pharmaceutical companies to set prices on some medicines, according to Reuters.

Pharma’s top 10 M&A deals of 2013

Top 10 M&A deals of 2013

Judge halts Massachusetts governor’s ban on powerful Zogenix painkiller

After last week expressing her opinion that Massachusetts Governor Deval Patrick was "out of line" with his move to block controversial superstrength painkiller Zohydro, U.S. District Court Judge Rya Zobel granted maker Zogenix's request for an injunction temporarily halting the ban.

New report finds Bydureon safest of new class of diabetes drugs

With big money to be made, drugmakers have responded to the global rise in Type 2 diabetes with a host of new classes of treatments that work in different ways. And while that is generally a good thing, the full range of adverse effects of all of these new drugs can't be known until they have been on the market for awhile, and some will fare better than others, a new report states.

Generics makers ask SCOTUS to let them proceed with Copaxone copies

Teva wants generics makers to hold off on launching their copies of multiple sclerosis drug Copaxone until the Supreme Court hears its appeal in a patent fight over the drug. And unsurprisingly, those generics companies are not that into the idea.

New drugs are J&J’s Q1 heroes, spurring pharma giant to hike 2014 forecast

Novartis marks 235 admin jobs for deletion amid companywide restructuring

View sitemap

ob_end_flush();